This comes after a second experimental COVID-19 vaccine by Moderna Inc. produced strong early results, saying its vaccine appears to be 94.5 per cent effective, according to preliminary data from an ongoing study.
About ten Covid-19 vaccines are now in phase 3 trials - the last stage of efficacy testing before a vaccine can be fully deployed in the wider population, reports Alliance for Science.
Pfizer announced in a tweet on Wednesday that its coronavirus vaccine candidate met all primary efficacy endpoints in a phase 3 clinical trial, and that it planned to file for emergency use authorization "within days".
Pfizer said it is confident in its existing cold-chain infrastructure to distribute the vaccine globally. Efficacy was consistent across age, gender, race and ethnicity demographics.
"Such high levels of efficacy reported in over 65 year olds surpasses all expectations we had for the first generation of COVID-19 vaccines", says Charlie Weller, head of vaccines at research charity Wellcome Trust.
The better-than-expected results from the two vaccines, both developed with new messenger RNA (mRNA) technology, have raised hopes for an end to a pandemic that has killed more than 1.3 million people and wreaked havoc upon economies and daily life.
BioNTech's Sahin said United States emergency use authorization (EUA) would be applied for on Friday.Читайте также: Russian mogul Fridman's plan is to save Dia with cutbacks and closed stores
US company Moderna, which is using similar technology to Pfizer, has also announced promising early results for its vaccine candidate, though that testing is ongoing.
Elliott made the announcement during Question Period in the Ontario legislature. Almost half of the total Phase 3 cohort were over the age of 56, and vaccine efficacy was still 94 percent in adults over 65 years of age. Of the 10 people who had severe COVID-19 infection, one had received the vaccine.
"With respect to the flu vaccine we did prioritize people in long-term care, people in hospitals and people living in congregate settings because we know that they are the most vulnerable and need to be protected". It isn't known how well the shot works in key subgroups, such as the elderly.
But the vaccine has to be stored at a temperature of minus 70 C or lower, possibly creating difficulty in its distribution process.
Pfizer said vaccine was well-tolerated and that side effects were mostly mild to moderate, and cleared up quickly.
Mike Ryan, the World Health Organization's top emergency expert, said it would be at least 4-6 months before significant levels of vaccination were taking place around the world. "The most common reactions were that 3.7 percent of participants experiencing fatigue and 2 percent had a headache, it said".При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2021 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог